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Background: Hyperproteinorrachia (raised cerebrospinal fluid total protein [CSF- TP]) 
without pleocytosis (HP) (also known as albuminocytologic dissociation) is identified 
in dogs with different neurologic diseases. However, the association between sur-
vival and increased CSF- TP is unknown.
Objectives: (a) Identify conditions commonly associated with HP in dogs and (b) in-
vestigate whether higher CSF- TP concentrations or other relevant factors are associ-
ated with 1- year survival.
Methods: This is a retrospective study that identified dogs with HP (Cisternal 
CSF- TP >0.30 g/L, Lumbar CSF- TP >0.45 g/L with total nucleated cell concentra-
tions [TNCCs] and RBC counts within RIs) from 2008 to 2019: recording signalment, 
weight, vital parameters, inflammation, neuroanatomic localization, CSF- TP, sampling 
site, final diagnosis, etiologic classification, and 1- year survival. Corrected CSF- TP was 
calculated as CSF- TP minus 0.3 (cisternal) or 0.45 (lumbar or unknown). Descriptive 
statistics were produced, CSF- TP differences between groups (eg, neuroanatomic 
localizations) were evaluated using the Mann- Whitney U test or Kruskal- Wallis test 
(post- hoc testing). The Cox proportional hazards model was used for survival data. 
Statistical significance was set at a P < 0.05.
Results: In all, 39 dogs had HP, associated with 17 conditions, including neoplasia 
(n = 6), meningoencephalitis of unknown origin (n = 4) (MUO), and intervertebral disc 
disease (n = 4) (IVDD) as the most common conditions. There was no significant dif-
ference between the CSF- TP/corrected CSF- TP between 1- year survivors and non- 
survivors, nor was there a difference between different neuroanatomic localizations 
or etiologic classifications (P > 0.05). Neoplasia, after adjustment for age, was the 
only variable associated with a worse survival (P = 0.01 HR: 2.08 (95% CI: 1.65- 39.2). 
CSF- TP was not associated with age (P > 0.05).
Conclusions: HP in dogs is associated with a wide range of conditions; the most com-
mon conditions are neoplasia, MUO, and IVDD. Higher CSF- TP levels do not correlate 
with a worse 1- year survival; however, they do correlate with neoplastic lesions.
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1  | INTRODUC TION
Hyperproteinorrachia without pleocytosis (HP) (also known as al-
buminocytologic dissociation) is defined by raised microprotein 
concentrations within cerebrospinal fluid (CSF)1 and can be seen in 
dog CSF samples analyzed by veterinary clinical pathologists. The 
increase in protein is attributed to either (a) local intrathecal immu-
noglobulin production (eg, seen with inflammatory or neoplastic dis-
eases) or neurologic tissue- derived proteins (eg, neurodegeneration 
leading to the release of cytoskeletal proteins), (b) increased blood- 
central nervous system (CNS) barrier permeability allowing blood- 
derived proteins to enter the CSF, or (c) interruption of CSF flow or 
absorption or, as is most likely, a combination of these scenarios.2 
The term albuminocytologic dissociation has not been used here as it 
does not accurately capture the associated pathophysiology leading 
to increased CSF total protein concentrations (CSF- TP); instead, it 
infers that hyperproteinorrachia is solely defined by albumin con-
centration increases. Many different disease processes can result 
in these circumstances; therefore, HP has a low specificity1,2 and, 
recent consolidated literature regarding HP in veterinary species is 
lacking. As a consequence, receiving a diagnosis of HP is largely de-
scriptive and frequently not informative for veterinarians.
The term albuminocytologic dissociation (HP without pleocyto-
sis) was first coined in 1912, describing the phenomenon in human 
patients with spinal cord compression.3 In human medicine, this 
finding is now associated with a wide variety of inflammatory (eg, 
Guillain- Barrè syndrome [GBS]), infectious (eg, viral meningitis), de-
generative, and neoplastic conditions.4 Recently, the importance of 
age- adjusted CSF- TP reference intervals has been described (with 
a small sex effect also reported), as human CSF- TP concentrations 
naturally elevate with increasing age, thus reducing the number of 
false- positive HP diagnoses.4 The same age- (and sex- ) association 
has not been widely reported within the veterinary literature. The 
magnitude of the protein elevation is not commonly reported as 
being an important criterion for clinical decision- making; however, 
Sahin et al (2017) identified a poorer 6- month prognosis (MRC Sum 
Score) in GBS patients with higher CSF- TP concentrations.5 This 
raises the question of whether the magnitude of CSF- TP elevation 
could be predictive of prognosis or survival in veterinary patients 
with HP.
Historically, canine CSF protein electrophoresis was conducted 
to quantify albumin and immunoglobulin proportions helping to 
elucidate underlying disease mechanisms at play, thus increasing 
specificity.6 This practice is now largely redundant with the advent 
of advanced diagnostics (eg, advanced imaging, infectious disease 
testing), allowing the diagnosis of specific neurologic conditions. 
However, not all cases can be extensively tested (eg, due to eco-
nomic constraints), and advanced imaging has specificity limitations 
(specifically distinguishing inflammatory from neoplastic lesions); 
therefore, if more recently published, consolidated data regarding 
HP- associated conditions and factors associated with survival were 
available, clinical applications would be more easily identifiable. 
Consequently, we aimed to (a) identify the most common conditions 
associated with HP within a UK population of dogs, (b) investigate 
whether a higher CSF- TP concentration is associated with reduced 
survival times, and (c) identify if any other risk factors in patients 
with HP are associated with survival times.
2  | MATERIAL S AND METHODS
2.1 | Data acquisition
Ethical approval for this study was obtained from the Department 
of Veterinary Medicine, University of Cambridge Ethics and Welfare 
Committee (CR359; 4/4/2019) in accordance with the University of 
Cambridge clinical research mandate. The patient record database 
from Central Diagnostic Services, University of Cambridge was 
searched for canine CSF samples with a microprotein result (2008- 
2019). HP cases were classified as having a CSF- TP concentration 
exceeding 0.30 g/L (cisternal) or 0.45 g/L (lumbar/no site recorded),1 
with a WBC count and RBC count not exceeding the upper reference 
intervals (WBC: 5 cells/µL and RBC: 8 cells/µL) (without a pleocyto-
sis). Those without increased CSF- TP concentrations or with pleocy-
tosis or hemodilution (ie, RBC count of >8 cells/µL) were excluded. 
No patients had repeated CSF analyses performed.
CSF- TP concentrations were analyzed on a Beckman Coulter 
AU480, using a pyrogallol red- molybdate complex, which is mea-
sured at 600 nm, according to the manufacturer's instructions. 
CSF- TP concentration was measured within 24 hours of sample col-
lection, often within 1- 2 hours.
Patient data (case number, species, breed, and sex) from the HP 
cases were collated, and presenting clinical examination, neuroana-
tomic localization (at admission), clinical pathology data, and defini-
tive diagnosis (if reached) were recorded. A definitive diagnosis was 
made by the attending board- certified neurologist using all available 
patient data, including advanced imaging investigation (magnetic 
resonance imaging) and/or confirmation with histopathology. After 
collection, all data were anonymized.
Patient survival (defined as being alive 1 year after the analysis 
date for the CSF sample that showed HP) was recorded for each in-
dividual, and initially, information was obtained from patient records. 
Where this information was not present, the referring veterinary 
surgeon was contacted.
2.2 | Statistical analysis
Statistical analyses were performed using either GraphPad Prism 
(Version 8.4.2 [464], GraphPad software) or R Statistics (Version 
3.6.3, The R project, https://www.r- proje ct.org) software. 
Statistical significance was set at P < 0.05, and two- sided analyses 
were used exclusively. The data obtained from all individuals were 
grouped, and descriptive statistics were calculated. Each patient's 
definitive diagnosis (or the suspected diagnosis from the attending 
board- certified veterinary neurologist) was assigned to an etiologic 
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classification, based on the DAMNITV (degenerative, anomalous, 
metabolic, neoplastic, iatrogenic, idiopathic, inflammatory/immune- 
mediated, toxic, traumatic, or vascular) classification.7 Corrected 
CSF- TP concentrations were calculated (CSF- TP concentrations 
[g/L] minus 0.30 [cisternal] or 0.45 [lumbar or unknown]) to account 
for the difference in protein reference interval limits at the two ac-
quiescent sites. Normality was assessed using a Shapiro- Wilk test. 
The difference in the CSF- TP concentrations was assessed among 
all the neuroanatomical localizations, including grouping by the cen-
tral nervous system (CNS), peripheral nervous system (PNS), brain 
(forebrain, cerebellum, and brainstem), and spinal cord (cervical and 
thoracolumbar regions). Then, the etiologic classifications were 
analyzed using a Kruskal- Wallis test with post- hoc testing (Tukey's 
multiple comparisons test) or a Mann- Whitney U test when only two 
groups were compared. The association between CSF- TP concen-
trations and age was evaluated using linear regression. For patients 
where the survival outcome was known at 1 year (all- cause mor-
tality), the CSF- TP concentrations were compared using a Mann- 
Whitney U test. Overall survival data were calculated using the 
Kaplan- Meier analysis for all patients. All individuals that survived 
to 1 year or where incomplete (<1 year) survival data was identi-
fied were right- censored. Hazard ratios were calculated using a Cox 
proportional hazard model for the following continuous variables; 
age, CSF- TP and corrected CSF- TP, weight, temperature, heart and 
respiratory rate at presentation, and categorical variables, breed 
(stratified as breed types, such as mixed breed and terrier- type), sex, 
neurologic localization, the presence of inflammatory changes on 
hematology and/or biochemistry panels (defined as an inflammatory 
leukogram or increased positive acute- phase proteins, respectively), 
and disease classification. If the assumptions for the Cox propor-
tional hazard model were violated, the n number was too low, or all 
individuals within that group were censored then the group was ex-
cluded from analysis. Schoenfeld residuals were calculated for each 
variable to ensure none violated the assumptions of proportional 
hazards.
3  | RESULTS
3.1 | Diseases associated with HP in dogs
From the records (748 CSF results with a microprotein value), 39 
dogs with HP were identified. An additional 14 dogs with HP were 
excluded due to hemodilution of the sample. The presence of HP 
was associated with 17 different conditions (Table 1), and of those 
with neoplasia (n = 6), the exact neoplasm was undetermined in 
three patients. Intervertebral disc disease and meningoencephali-
tis of unknown origin (MUO) were the most commonly associated 
conditions. Definitive diagnosis of neoplasia was obtained in 4/6 
patients through histologic examinations (either ante- mortem bi-
opsies or post- mortem examination), including hemangiosarcoma 
(n = 1) and peripheral nerve sheath tumor (n = 3). Neoplasia was 
suspected in two others (lymphoma and one undetermined).
3.2 | CSF- TP in patients with HP
Descriptive data are summarized in Table 2A. The mean (±SD) 
CSF- TP concentration of all patients was 0.59 + 0.33 g/L with the 
predominant CSF sample site was cisternal (n = 26) (lumbar; n = 9, 
and not recorded; n = 4). The mean corrected CSF- TP concentra-
tion was 0.21 + 0.25 g/L. When separated by neuroanatomic lo-
calizations (Figure 1) or etiological classifications (Figure 2), there 
was no significant statistical difference between the CSF- TP con-
centrations (P > 0.05) across any of the subcategories. CSF- TP 
concentration was not associated with the age of the animal 
(P > 0.05) (Figure S1).
3.3 | CSF- TP and survival in patients with HP
Complete patient survival at 1 year post- HP identification was 
available for 21 patients, and within this group there was no differ-
ence in the CSF- TP or corrected CSF- TP concentrations between 
TA B L E  1   Underlying conditions associated with 
hyperproteinorrhachia (HP) in 39 dogs




Intervertebral disc disease 4




Supracollicular fluid accumulation 1
Congenital vertebral malformation 1
Neoplasia 6
Inflammatory 8
Meningoencephalitis of unknown origin 4





Idiopathic peripheral vestibular disease 1
Toxic 2
Potassium bromide toxicity 1
Toxic insult; unknown agent 1
Vascular 5
Vascular lesion; undetermined 3
Fibrocartilaginous embolic myelopathy 2
Undetermined 2
DAMNITV: degenerative, anomalous, metabolic, neoplastic, iatrogenic, 
idiopathic, inflammatory/immune- mediated, toxic, traumatic, or 
vascular.
4  |     DRAPER Et Al.
TA B L E  2   Summary of the descriptive statistics from dogs with HP for the entire dataset (n = 39; All) (A) and for the survival data (n = 29) 
(B), including covariates analyzed using a Cox Proportional Hazard analysis. Dogs labeled as Other Dog breeds included Weimaraner, French 





CSF protein (g/L) 0.59 (±0.32)
Corrected CSF protein (g/L) 0.21 (±0.25)
Weight (kg) 20.6 (±11.7)















Vital parameters at presentation
Temperature (℃) 38.2 (±0.60)
Pulse (per min) 94 (±23)
Respiration (per min) 26 (±9)
Neurological localization
CNS: Forebrain/brainstem/cerebellum 15
CNS: Cervical (C1- C5) 4
CNS: Brachial SC (C6- T2) 1
CNS: Thoracolumbar (T3- L3) 7
CNS: Lumbosacral SC (L4- S2) 4
PNS 6
Multifocal 2











CSF protein (g/L) 0.51 (±0.21) −0.76 0.47 0.008- 26.7 0.71
Corrected CSF protein (g/L) 0.16 (±0.20) 0.08 1.09 0.02- 52.7 0.97
Weight (kg) 19.4 (±10.1) −0.05 0.94 0.87- 1.027 0.19
Age (y) 7.7 (±3.0) 0.27 1.30 1.0- 1.71 0.05
(Continues)
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animals that survived to 1 year (CSF- TP 0.44 ± 0.12 g/L and cor-
rected CSF- TP 0.11 ± 0.11 g/L; n = 12) and non- survivors (CSF- TP 
0.46 ± 0.20 g/L and corrected CSF- TP 0.14 ± 0.15 g/L; n = 9) 
(P > 0.05) (Figure 3).
Survival data were available for 29 patients (eight patients 
had incomplete survival data; known to be alive on a set day less 
than 365 days after the HP diagnosis). Nine patients did not sur-
vive to 1 year, and all were euthanized as a direct result of their 
neurologic status or condition (neoplasia n = 5, vascular n = 3, 
and idiopathic n = 1). When stratified by etiologic classification, a 
diagnosis of neoplasia was associated with a significantly shorter 
survival time (median survival time (MST) = 22 days, survival 
range = 1- 180 days) compared with all other categories (P < 0.001) 
(Vascular MST = 341 days, survival range = 4- 365 days) (Figure 4). 
The univariable analysis identified neoplasia as being negatively cor-
related with survival (P < 0.05, Hazard Ratio (HR): 11.07) (Table 2B) 
when the non- neoplastic diseases were combined and compared 
with neoplastic diseases.
Increasing age is associated with the development of some types 
of neoplasia within the nervous system.8 After adjustment for age, 
a diagnosis of neoplasia remained significantly associated with re-
duced survival to 1 year in the HP patients (survival ~ disease clas-
sification + age; disease classification – P = 0.01 HR: 2.08 [95% CI: 
1.65- 39.2], Age – P = 0.36 HR: 1.14 [95% CI: 0.86- 1.54]).
(B)







Male 16 −0.27 0.77 0.20- 2.90 0.70
Female 13 Referent
Breed
“Other” dog breeds 11 Referent
Terrier 9 2.49 12.01 0.98- 72.00 0.06
Spaniel 5 1.79 5.99 0.54- 66.72 0.15
Retrievers 4 0.97 2.65 0.17- 42.30 0.49
CSF collection site
Cisternal 21 Referent
Lumbar/not reported 8 −1.14 0.32 0.04- 2.57 0.28
Vital parameters at presentation
Temperature (℃) 38.1 (±0.50) 0.23 1.26 0.31- 5.2 0.74
Pulse (per min) 90 (±20) −0.01 0.99 0.95- 1.028 0.55
Respiration (per min) 27 (±9) 0.015 0.98 0.89- 1.15 0.82
Neurologic localization
CNS 13 Referent
PNS 5 1.10 3.00 0.71- 12.65 0.13
Multifocal 3 0.27 1.31 0.15- 11.23 0.81
Hematologic markers of inflammation present
Yes 4 Referent
No 12 0.48 1.61 0.18- 13.8 0.66
Disease categorization (DAMNITV)









TA B L E  2   (Continued)
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4  | DISCUSSION
This retrospective study highlighted that canine HP is associated 
with many different conditions, confirming its lack of specificity to 
a particular canine neurologic condition. In addition, the authors 
suggest that clinical pathology terminology should substitute albu-
minocytologic dissociation with HP to reflect all possible pathophys-
iologic abnormalities accurately.
The most common conditions associated with HP were neopla-
sia, MUO, and IVDD, which collectively, to the best of the authors’ 
knowledge, have not been previously reported in the veterinary 
literature. However, this is in line with other research articles in-
vestigating the clinicopathologic features of individual neurological 
diseases.8- 11 Interestingly here, three dogs with HP associated with 
neoplasms were diagnosed with peripheral nerve sheath tumors, 
whereas HP has been more commonly associated with intracranial 
neoplasias.8 HP is known to occur with extradural synovial cysts and 
type 1 intervertebral disc herniation causing chronic compressive 
myelopathy in dogs,10,12 resulting from impaired CSF flow and local-
ized inflammation.
F I G U R E  1   Graphical depiction of cerebrospinal fluid total 
protein (CSF- TP) concentrations in dogs with hyperproteinorrachia 
without pleocytosis (HP) grouped by different neuroanatomic 
localizations A, reported CSF- TP concentrations (non- corrected 
CSF- TP [NC]) B, Corrected CSF- TP (corrected [C]). No statistically 
significant differences were noted between any of the group 
comparisons. Dots reflect individual patient values, with the mean 
and standard deviation
F I G U R E  2   Graphical depiction of cerebrospinal fluid total 
protein (CSF- TP) concentrations in dogs with hyperproteinorrachia 
without pleocytosis (HP) grouped by different disease 
classifications (DAMNITV). A, reported CSF- TP concentrations 
(non- corrected CSF- TP [NC]). B, Corrected CSF- TP (corrected [C]). 
No statistically significant differences were noted between any 
of the group comparisons. Dots reflect individual patient values, 
with the mean and standard deviation. DAMNITV, degenerative, 
anomalous, metabolic, neoplastic, iatrogenic, idiopathic, 
inflammatory/immune- mediated, toxic, traumatic, or vascular
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This is also the first paper evaluating the survival to 1 year of 
dogs with HP irrespective of the underlying etiopathogenesis or con-
dition; survival in MUO patients was not reported to be associated 
with CSF- TP concentrations.9 No correlation between CSF- TP con-
centrations (including when correct for the sampling site) and sur-
vival was identified, and while this might be a true reflection of HP, 
the heterogeneity of the conditions included could also have influ-
enced this lack of a correlation. Notwithstanding, grouping the con-
ditions into general categories of disease etiology (eg, degenerative 
conditions) did not highlight any significant differences in CSF- TP 
that could have been influenced by the inclusion of other condi-
tions. Indeed, neoplastic conditions were associated with the poor-
est 1- year survival, and these HP cases typically had only modest 
CSF- TP elevations (Figures 2 and 3). However, expanding this study 
to include more individuals from the most common diseases present 
would have allowed more disease- specific statements to be made.
Unsurprisingly, adverse 1- year survival in dogs with HP was only 
associated with neoplasia (even after adjustment for age). Neoplasia 
of the nervous system has been reported to have poor survival in 
dogs, given the challenges resulting from a lack of efficacious ther-
apies, space- occupying lesions within the CNS, and severe compro-
mise to an animal's quality of life.8 However, the elevation of CSF- TP 
in dogs with neoplasia appears to depend on the location and type 
of the neoplasia, such as choroidal plexus carcinomas, which have 
been shown to have very high CSF- TP often attributed to altered 
endothelial cell permeability and basement membrane integrity.13 
No choroidal plexus tumors were included in this population of dogs.
We also found no difference in CSF- TP and neuroanatomic local-
izations, which could reflect sampling remote from the site of pathol-
ogy; a recent study has also highlighted that CSF should be sampled 
at the site closest to the neuroanatomic localization to gain a true 
F I G U R E  3   Graphical depiction of cerebrospinal fluid total 
protein (CSF- TP) concentrations in dogs with hyperproteinorrachia 
without pleocytosis (HP) showing there was no statistically 
significant difference between CSF protein levels (with non- 
corrected CSF- TP values [NC] or with corrected CSF- TP values 
[C]) of 1- year survivors (Surv) and non- survivors (Non- Surv). Each 
individual patient value is represented, with the mean and standard 
deviation; red dot— patients with neoplasia, blue dot— patients 
with a degenerative condition, black star— patients with a vascular 
condition, green cross— patients with an inflammatory condition, 
black inverted triangle— patients with an idiopathic condition, black 
diamond— patient with an anomalous condition, black triangle— 
patient with a toxic condition and a black circle— patient with an 
undetermined condition classification
F I G U R E  4   Kaplan- Meier survival plots for all dogs with hyperproteinorrachia without pleocytosis (HP) (left) (dotted lines: 95% 
confidence intervals), and those dogs with HP stratified by disease classification whereby dogs with HP and neoplasia had a statistically 
significant shorter survival time (median survival time of 22 days) (P = 0.0007) compared with the “Other” disease classifications. Censored 
individuals are plotted with a vertical line. Patients with toxic, undetermined, and anomalous conditions are not shown (n = 1 survival to 
1 year per condition)
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reflection of the focal neurologic environment.14 The neurology ser-
vice at the University of Cambridge typically chooses the sampling 
site closest to the neuroanatomic localization, which was reflected 
by most sampling sites being from lumbar sites in dogs with neuro-
anatomic localizations caudal to the thoracolumbar spine (7/9).
Age- specific reference intervals for CSF- TP have recently been 
recommended in people.4 No data have been published to support 
this need in canine patients. Age- corrected canine CSF- TP reference 
intervals would be difficult to achieve due to the different life expec-
tancies associated with different breeds. Therefore, it is important 
to report that this study did not find any association between age 
and CSF- TP levels, indirectly suggesting that this association might 
not be a phenomenon in aged dogs. Further studies investigating an 
association between CSF- TP concentrations and age in non- diseased 
dogs would need to be performed to corroborate these findings.
The inclusion criteria for this study were stringent, whereby 
any hemodiluted samples were excluded. It has been reported that 
moderate hemodilution (RBC <13 200 cells/mm3) does not cause a 
significant increase in the CSF- TP15; however, even a small elevation 
in CSF- TP could cause the inclusion of false- positive HP cases, po-
tentially leading to incorrect conclusions being drawn.
The three main limitations of this research include the retrospec-
tive nature of the study, the relatively low number of dogs included, 
and, potentially, differences in sample acquisition times between in-
dividuals and the stage of disease. The archives were searched over 
an 11- year period, and only approximately 5% of the CSF samples 
with a CSF- TP result were identified as having HP. This low number 
also precluded disease- specific survival analysis. Therefore, multi- 
center studies would be needed to expand case numbers, which 
could allow further analyses to be performed.
The timing of sample acquisition was not standardized across 
the HP cases included, as this is individually recommended based on 
disease presentation. Consequently, it means that some dogs may 
have been sampled during the acute phase of the underlying disease, 
whereas others could have been sampled during the chronic or re-
solving phases. As the aim of this study was to investigate different 
conditions that result in HP and the relationship of HP to survival, the 
lack of a standardized CSF sampling time point is likely less important 
than if a sole condition associated with HP was being investigated.
In conclusion, HP in dogs is associated with a wide range of 
conditions, most commonly neoplasia, MUO, and IVDD. The higher 
CSF- TP concentrations did not correlate with a worse 1- year sur-
vival; however, neoplastic lesions do. Increasing age in dogs does not 
appear to be associated with increasing CSF- TP concentrations.
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